5,745 Axsome Therapeutics, Inc. $AXSM Shares Bought by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. raised its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 22.4% during the third quarter, HoldingsChannel reports. The firm owned 31,373 shares of the company’s stock after buying an additional 5,745 shares during the period. Jefferies Financial Group Inc.’s holdings in Axsome Therapeutics were worth $5,785,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Machina Capital S.A.S. purchased a new stake in Axsome Therapeutics during the 3rd quarter valued at approximately $632,000. Illinois Municipal Retirement Fund grew its stake in shares of Axsome Therapeutics by 72.6% in the 3rd quarter. Illinois Municipal Retirement Fund now owns 13,818 shares of the company’s stock valued at $2,548,000 after purchasing an additional 5,812 shares during the last quarter. Csenge Advisory Group grew its stake in shares of Axsome Therapeutics by 24.7% in the 3rd quarter. Csenge Advisory Group now owns 2,577 shares of the company’s stock valued at $475,000 after purchasing an additional 510 shares during the last quarter. New York Life Investment Management LLC acquired a new position in shares of Axsome Therapeutics in the third quarter valued at approximately $1,088,000. Finally, M&G PLC increased its holdings in shares of Axsome Therapeutics by 1.2% in the third quarter. M&G PLC now owns 59,697 shares of the company’s stock valued at $10,984,000 after purchasing an additional 721 shares during the period. Hedge funds and other institutional investors own 81.49% of the company’s stock.

Axsome Therapeutics Stock Performance

NASDAQ AXSM opened at $144.37 on Friday. The business has a fifty day moving average of $172.78 and a 200-day moving average of $196.98. Axsome Therapeutics, Inc. has a fifty-two week low of $123.00 and a fifty-two week high of $260.19. The stock has a market cap of $7.59 billion, a price-to-earnings ratio of -47.18 and a beta of 0.86. The company has a quick ratio of 1.34, a current ratio of 1.42 and a debt-to-equity ratio of 1.21.

Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings results on Monday, November 2nd. The company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.38. Axsome Therapeutics had a negative return on equity of 198.73% and a negative net margin of 18.18%. The company had revenue of $259.69 million for the quarter, compared to analyst estimates of $249.19 million. During the same quarter in the prior year, the company posted ($0.94) EPS. The business’s revenue for the quarter was up 51.9% compared to the same quarter last year. As a group, analysts predict that Axsome Therapeutics, Inc. will post -2.27 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on AXSM shares. Zacks Research upgraded Axsome Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 18th. Piper Sandler lowered their price objective on shares of Axsome Therapeutics from $258.00 to $238.00 and set an “overweight” rating on the stock in a research report on Monday, October 26th. Guggenheim dropped their price objective on shares of Axsome Therapeutics from $275.00 to $250.00 and set a “buy” rating on the stock in a research note on Tuesday, November 3rd. Deutsche Bank reduced their target price on shares of Axsome Therapeutics from $280.00 to $267.00 and set a “buy” rating for the company in a research note on Tuesday, September 29th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Axsome Therapeutics in a report on Thursday, October 15th. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $267.58.

Insider Buying and Selling

In related news, COO Mark Jacobson sold 10,000 shares of the company’s stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $208.65, for a total value of $2,086,500.00. Following the completion of the transaction, the chief operating officer directly owned 10,000 shares in the company, valued at approximately $2,086,500. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 20.60% of the company’s stock.

About Axsome Therapeutics

Axsome Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for central nervous system disorders. The company is headquartered in New York and is led by founder, chairman and chief executive officer Herriot Tabuteau. Its marketed products include Auvelity, an oral treatment for major depressive disorder in adults, and Sunosi, which is used to improve wakefulness in adults with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.